• DUPIXENT is now recommended for specific use in England and Wales1


    Use the map to view DUPIXENT reimbursement for the specific regions.

    NICE Technology Appraisal Guidance (TA751)1

    DUPIXENT is recommended by National Institute for Health and Care Excellence (NICE), as an add-on maintenance therapy option for treating severe asthma with Type 2 inflammation that is inadequately controlled in people 12 years and over, despite maintenance therapy with high-dose inhaled corticosteroids and another maintenance treatment, only if the below criteria are met1

    The person has agreed to and followed the optimised standard treatment plan

    The dosage used is 400 mg initially and then 200 mg subcutaneously every other week

    Blood eosinophils (EOS) ≥150 cells/μL and fraction of exhaled nitric oxide (FeNO) ≥25 ppb

    The person has had ≥4 exacerbations in the preceding year

    The person is not eligible for biologicals or has asthma that has not responded adequately to biological therapy

    The company provides DUPIXENT with the discount agreed in the patient access scheme (PAS)

    Stop dupilumab if the rate of severe asthma exacerbations has not been reduced by at least a 50% after 12 months.

  • DUPIXENT has specific guidance for use in Scotland2


    In Scotland, DUPIXENT is accepted for restricted use for severe asthma in patients 12 years and older with blood eosinophils (EOS) ≥150 cells/mL and fraction of exhaled nitric oxide (FeNO) ≥25 ppb, and ≥4 exacerbations in the preceding year, who have previously received biologic treatment with anti-IgE or anti-IL-5 therapies2

    Use the map to view DUPIXENT reimbursement for the specific regions.

    Scottish Medicines Consortium (SMC) advice2

    SMC have restricted the use of DUPIXENT to patients with blood EOS ≥150 cells/μL and FeNO ≥25 ppb, and ≥4 exacerbations in the preceding year, who have previously received biologic treatment with anti-IgE or anti-IL-5 therapies

    SMC reviewed DUPIXENT under the context of its indication: as add-on maintenance treatment for severe asthma in adults and adolescents 12 years and older with Type 2 inflammation characterised by raised blood EOS and/or raised FeNO, who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment

    The SMC advice applies to an approved Patient Access Scheme (PAS) that delivers the cost-effectiveness of DUPIXENT or a PAS/list price that is equivalent or lower


Mode of action
DUPIXENT

Have questions about how DUPIXENT works?





Find out more


DUPIXENT efficacy


Want to know how DUPIXENT can help your patients? Find out more about the Phase 3 clinical trials of DUPIXENT.



Find out more


Dosing


Learn more about how DUPIXENT can be administered.




Find out more

    EOS, eosinophils; FeNO, fraction of exhaled nitric oxide; ICS, inhaled corticosteroids; IgE, immunoglobulin E; IL, interleukin; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; PAS, Patient Access Scheme; ppb, parts per billion; SMC, Scottish Medicines Consortium.

    References

    1. NICE guidance. Available at: https://www.nice.org.uk/guidance/gid-ta10276/documents/final-appraisal-determination-document. Date accessed: June 2022
    2. Scottish Medicines Consortium. Dupilumab (Dupixent). Available at: https://www.scottishmedicines.org.uk/medicines-advice/dupilumab-dupixent-full-smc2317/. Date accessed: December 2021.

MAT-GB-2100503(v7.0) | Date of preparation: June 2022